Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins

X. Kang, P. F. Robbins, E. B. Fitzgerald, R. F. Wang, S. A. Rosenberg, Y. Kawakami

Research output: Contribution to journalArticle

Abstract

Several epitopes in the human melanoma antigens recognized by HLA-A2- restricted CTLs have a relatively low MHC-binding affinity and as a result may be expressed at very low densities on the cell surface, indicating that these epitopes may not be efficient immunogens. To express these epitopes at higher densities on the surface of antigen-presenting cells and therefore improve their immunogenicity, a DNA construct in which a cDNA fragment encoding the melanoma epitope MART-127-35 or gp100280-288 was inserted between sequences encoding the leader and the HLA-A* 0201 protein. Cells transfected with these epitope-HLA fusion constructs were recognized by HLA-A2-restricted melanoma-reactive CTLs specific for the MART-1 or gp100 epitope. In addition, tumor-reactive CTLs could be induced from PBMCs of patients with metastatic melanoma by in vitro stimulation with HMY-C1R B- cell lines expressing the MART-1 or gp100 epitope-HLA-A* 0201 fusion protein. These epitope-HLA fusion constructs may be useful for the development of immunotherapies for patients with melanoma.

Original languageEnglish (US)
Pages (from-to)202-205
Number of pages4
JournalCancer Research
Volume57
Issue number2
StatePublished - Jan 28 1997

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins'. Together they form a unique fingerprint.

  • Cite this

    Kang, X., Robbins, P. F., Fitzgerald, E. B., Wang, R. F., Rosenberg, S. A., & Kawakami, Y. (1997). Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins. Cancer Research, 57(2), 202-205.